{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-26-000003","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.995093+00:00","generated_at":"2026-05-16T11:00:17.976961+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Myriad Genetics prelim Q4 revenue $207-209M, FY25 $822-824M; FY26 guidance $860-880M","bullets":["Preliminary Q4 2025 total revenue $207-209M; full year 2025 revenue $822-824M.","Full year 2025 test volumes ~1.5M (+1% YoY): hereditary cancer +7%, mental health +6%, prenatal -4%.","FY 2026 revenue guidance $860-880M (midpoint +6% vs FY25 prelim midpoint).","FY 2026 adjusted gross margin guidance 68-69%; adjusted EBITDA $37-49M (midpoint +43% vs prior FY25 guide).","Formal Q4/FY 2025 earnings call scheduled for February 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-26-000003","json":"https://secwatch.observer/filing/0000899923-26-000003.json","markdown":"https://secwatch.observer/filing/0000899923-26-000003.md","text":"https://secwatch.observer/filing/0000899923-26-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992326000003/0000899923-26-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992326000003/mygn-20260112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:00:17.976961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}